Bioverativ (Bioverativ) COGS-to-Revenue : 0.21 (As of Dec. 2017)

View and export this data going back to 2017. Start your Free Trial

What is Bioverativ COGS-to-Revenue?

Bioverativ's Cost of Goods Sold for the three months ended in Dec. 2017 was $70 Mil. Its Revenue for the three months ended in Dec. 2017 was $329 Mil.

Bioverativ's COGS to Revenue for the three months ended in Dec. 2017 was 0.21.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Bioverativ's Gross Margin % for the three months ended in Dec. 2017 was 78.61%.

Bioverativ COGS-to-Revenue Historical Data

The historical data trend for Bioverativ's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioverativ COGS-to-Revenue Chart

Bioverativ Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

COGS-to-Revenue

0.26

0.09

0.27

0.24

Bioverativ Quarterly Data
	Dec13	Dec14	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17
COGS-to-Revenue	Get a 7-Day Free Trial							0.30	0.24	0.28	0.22	0.21

Bioverativ COGS-to-Revenue Calculation

Bioverativ's COGS to Revenue for the fiscal year that ended in Dec. 2017 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	279.6	/	1168.5
	=	0.24

Bioverativ's COGS to Revenue for the quarter that ended in Dec. 2017 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	70.3	/	328.7
	=	0.21

Bioverativ (NAS:BIVV) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Bioverativ's Gross Margin % for the three months ended in Dec. 2017 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	70.3 / 328.7
	=	78.61 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Bioverativ COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Bioverativ's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioverativ (Bioverativ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioverativ Inc (NAS:BIVV) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.bioverativ.com

Bioverativ Inc is a biotech focused on rare blood disorders and has two marketed hemophilia products: Eloctate (hemophilia A) and Alprolix (hemophilia B). Bioverativ spun off from Biogen in February 2017. Bioverativ's partner Swedish Orphan Biovitrum holds rights to these therapies and pipeline hemophilia therapies in many markets outside the U.S. Bioverativ is building a pipeline in rare blood-related disorders, such as TNT009 (part of the True North acquisition) in cold agglutinin disease and other hematology-focused drug candidates. Sanofi's pending acquisition of Bioverativ was announced in January 2018.

Executives

Alexander J Denner	director	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Brian S Posner	director	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
John Cox	director, officer: Chief Executive Officer	C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
John Greene	officer: EVP, CFO and Treasurer	51 LIME STREET, LONDON X0 EC3M 7DQ
Geno J Germano	director	5 GIRALDA FARMS, MADISON NJ 07940
Louis J Paglia	director	C/O UIL HOLDINGS CORP, 157 CHURCH STREET, NEW HAVEN CT 06506
Anna Protopapas	director	MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Diantha Duvall	officer: Chief Accounting Officer	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Vivaldi Coelho Rogerio	officer: EVP, Chief Global Therapeutics	225 SECOND AVENUE, WALTHAM MA 02451
Harris Timothy J.r.	officer: EVP, R & D	C/O BG MEDICINE, 610 LINCOLN STREET NORTH, WALTHAM MA 02451
Lucia Celona	officer: EVP, HR & Corp Commun. Officer	BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Richard Brudnick	officer: EVP, Business Development	BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Biogen Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142

Bioverativ (Bioverativ) Headlines

From GuruFocus

Seeking Value in Biotech: Bioverativ

By Mark Yu Mark Yu • 06-29-2017

5 Companies Hit 52-Week Highs

By yifan900 yifan900 • 05-29-2018

Jeff Ubben Buys 1, Sells 1 in 1st Quarter

By Sydnee Gatewood Sydnee Gatewood • 05-24-2017